Dr Jeremy Rees
Telephone:
Email:
Location:
- University College Hospital
- National Hospital for Neurology and Neurosurgery
GMC/GDC number:
3196139
Professional background
Dr Jeremy Rees qualified in 1988 from University College and Middlesex Medical School with distinctions in medicine, surgery and therapeutics. After postgraduate training, including a spell at Memorial Sloan Kettering Hospital, New York, in 1999 he was appointed as honorary senior lecturer in neuro-oncology and consultant neurologist at the National Hospital for Neurology and Neurosurgery. He specialises in the management of low-grade brain tumours and neurological complications of cancer and cancer treatments.
He has been clinical lead for the brain tumour unit at Queen Square, the pathway director for brain cancer at London Cancer and was the neurology expert member of the NICE guidelines committee, which published national guidelines on the treatment of primary and secondary brain tumours in 2018.
He leads a research team investigating the role of multimodality imaging in the management of low grade gliomas, has edited a textbook on neuro-oncology, written numerous peer-reviewed research papers and chapters on neuro-oncology. He runs an educational course on neuro-oncology and lectures extensively to different professional groups.
Specialties
Research interests
Low grade gliomas, imaging of brain tumours
Publications
Book Chapters
1. Neuro-oncology. Fersht N, McEvoy A and Rees JH in Clinical Neurology 5th Edition
2. ‘Imaging of Treatment Response and Pseudoresponse’. Thust S, Hyare H and Rees JH in Glioblastoma: State-of-the-Art Clinical Neuroimagingeds Iv M, Wintermark M, Massoud TF. Nova, 2019
3. ‘Drugs in Neuro-oncology’ Ledingham D and Rees JH. in Drugs in Neurology eds Nageshwaran S,
Ledingham D and Wilson HC. Oxford University Press 2017
4. ‘Neuro-oncology’ JH Rees, HR Jager, N Fersht, S Brandner, R Bradford and E Wilson
Queen Square Textbook 2nd Edn, eds Clark, Shorvon, Rossor, Howard. Blackwell, 2016
5. ‘Intracranial Tumours’ and ‘Paraneoplastic Neurological Syndromes’ JH Rees
Oxford Textbook of Medicine 6th Edn; eds Warrell, Cox, Firth and Benz. Oxford, 2018
Peer-Reviewed Publications
1. Dumas AA, Pomella N, Rosser G et al. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. The EMBO Journal 2020; e103790. doi: 10.15252/embj.2019103790
2. Solomons M, Jaunmuktane Z, Weil RS, El Hassan T, Brandner S, Rees JH. Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better. Neuro-Oncology Practice, 2020. 7:196-201 doi: 10.1093/nop/npz056. Epub 2019 Nov 21
3. Roberts TA, Hyare H, Agliardi G, et al Noninvasive Diffusion Magnetic Resonance Imaging of Brain Tumour Cell Size for the Early Detection of Therapeutic Response. Sci Rep 2020 10:9223 doi: 10.1038/s41598-020-65956-4.
4. Hyare H, Rice L, Thust S et al. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status. Eur J Radiol 2019;May doi: /10.1016/j.ejrad.2019.03.003
5. Thust SC, Hassanein S, Bisdas S, Rees JH et al. Apparent Diffusion Coefficient for Molecular Subtyping of non-gadolinium-enhancing WHO II/III glioma: volumetric segmentation versus two-dimension region of interest analysis. EurJ Radiol 2018;Mar 23 doi: 10.1007/s00330-018-5351-0.
6. Kosmin M, Solda F, Wilson E, Kitchen N, Rees J, Fersht N. The impact of route of diagnosis on survival in patients with glioblastoma. Br J Neurosurg 2018; 32: 628-630 doi: 10.1080/02688697.2018.1436693. Epub 2018 Feb 9.
7. Spain L, Walls G, Julve M et al. Neurology from immune checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 2017; 28: 377-385
8. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Baumert B, Hegi MR, van den Bent M et al. Lancet Oncology 2016;17: 1522-1532
9. Acute demyelination following radiotherapy for glioma: a cautionary tale. Milic M, Rees JH Practical Neurology 2017; 17: 35-38
10. Diagnostic delay and survival in high grade gliomas – evidence of the “waiting time paradox”? Aggarwal A, Herz N, Campbell P, Arkush L, Short S, Rees J. Br J Neurosurg 2015 ; 4: 1-4
Reviews
Neurotoxicity – CAR T-cell therapy: what the neurologist needs to know. Neill L, Rees JH, Roddie C. Practical Neurology 2020; doi: 10.1136/practneurol-2020-002550